Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
about
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionHepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in EuropeGlobal epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypesPublic health and international drug policy.Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, CanadaPrevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis.A public health approach to hepatitis C control in low- and middle-income countries.Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.Commentary on Nolan et al. (2014): Opiate substitution treatment and hepatitis C virus prevention: building an evidence base?Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs?Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China.Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence.Human immunodeficiency virus and liver disease: An update.Characterizing the Burden of Hepatitis C Infection Among Entrants to Pennsylvania State Prisons, 2004 to 2012.The Impact of Enhanced Screening and Treatment on Hepatitis C in the United StatesChronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationCIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and TreatmentNew treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in EnglandLiver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease BurdenThe 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C.The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review.Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review.Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.Potential bias due to outcome-related loss to follow-up in cohort studies on incidence of drug injection: systematic review and meta-analysis.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Hepatitis C: Review of the Epidemiology, Clinical Care, and Continued Challenges in the Direct Acting Antiviral Era.
P2860
Q26801456-8BBE24DC-D94A-4377-BE5F-A6EE5C945403Q28079580-CD5F3C0E-F1B2-4F82-90EC-853DF88EF4DFQ30245058-4DB8F82C-1547-4A5C-9EB7-96F9111FD670Q30377895-5260B25A-685A-4209-8814-08EF91884A11Q30429470-A63016BE-6068-479F-BBEB-DC0080EDAC7AQ33769960-27CC60D5-666A-497C-88A0-449E30B302A5Q33853664-EF3DB97D-4EB4-4B9D-9B92-97A0412998FCQ34028058-9BFEFA05-00FC-4F74-A974-3A893FEE0490Q34415820-266769D0-AA16-4602-B885-A17D2CF42472Q34511438-A4F9EA55-38D2-44B4-BCFA-0694B4898C40Q35164735-EEB8E644-CC3A-4E91-BC21-551240C88126Q35237341-8E3A612F-1AFB-4759-8A5A-CD48E126EE79Q35535844-4232E39C-995F-425D-91F4-B4D50E7996B4Q35565944-ABD9C61D-BB08-4266-B1E8-72C091D7D203Q35750560-DFCF75D5-172E-461D-9B5A-1580405C5F27Q35865346-E93F45BD-9543-4ACD-BAFE-04E0F64945D9Q35903698-689EBBFF-D283-47C6-8465-D4C417740F79Q35998417-FA021628-80C2-423D-AF6C-21ADFC2FC6DCQ36137709-854B7AD0-9494-4A5F-8F18-0371DB18E16AQ36192804-BD081495-3125-4569-8D49-FA75CC098661Q36286654-6D69DE9F-3F77-471B-96B2-BE9AB5BB8E65Q36319803-0CFEA3E4-AECA-46A6-8E52-B3A9514465DFQ36378109-2CCEDC1F-C6DB-4868-B1A9-9F67F57402A2Q36382409-4039E620-D6C5-45FE-8CA4-D1B32BCC3F40Q36446133-B878E2A2-9E38-4B95-8F11-506AF9ECDA65Q36828161-21B10F2D-2F51-46EA-A91B-B198A593E1E0Q37023539-3F6A67A4-65A6-4D2E-8855-069A0FC96495Q37100669-8CEB17B3-D61E-45B9-94EF-A1FDEC1FC0F0Q37169457-850B7306-9D6E-4C42-8894-59D10B6918B4Q37246465-E966DCBB-7E06-49BC-88C8-9E5C306B8014Q37397011-8223A161-6DB8-4561-B7D2-2BFC7D62FAA3Q37455611-48204A46-C26B-4405-A3DE-EC7D7CC3CA7EQ38205937-CEC0BCB3-4CD6-42E8-A648-717045D222EEQ38255693-03C3184C-344B-4CE9-BF3B-32F702793BECQ38380343-79B06A1D-5842-4228-AB09-29F93CACC6FEQ38387667-5CEF2992-B5B5-49B7-9A72-209DD8999283Q38407579-6832BF65-EB0C-4CEF-9D43-D3107B6E81FCQ38573508-70ABA30A-5997-4CF8-88A8-97B7AA8BF85EQ38613271-0EFB9499-A4AD-417A-B625-3764DB719BC9Q38635796-ED447B9D-37B0-4953-AA2C-817F852DE53C
P2860
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Combination interventions to p ...... d opiate substitution therapy.
@en
Combination interventions to p ...... d opiate substitution therapy.
@nl
type
label
Combination interventions to p ...... d opiate substitution therapy.
@en
Combination interventions to p ...... d opiate substitution therapy.
@nl
prefLabel
Combination interventions to p ...... d opiate substitution therapy.
@en
Combination interventions to p ...... d opiate substitution therapy.
@nl
P2093
P2860
P356
P1476
Combination interventions to p ...... d opiate substitution therapy.
@en
P2093
David J Goldberg
Natasha K Martin
Sharon J Hutchinson
P2860
P304
P356
10.1093/CID/CIT296
P407
P433
P478
57 Suppl 2
P577
2013-08-01T00:00:00Z